metoclopramide and Bleeding studies

Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.

Research Excerpts

Excerpt	Relevance	Reference
"Although metoclopramide (MCP) administration after trauma-hemorrhage restores the depressed immune functions, it remains unknown whether this agent has any salutary effects on the depressed cardiovascular and hepatocellular functions under those conditions."	7.70	Metoclopramide: a novel adjunct for improving cardiac and hepatocellular functions after trauma-hemorrhage. ( Bland, KI; Chaudry, IH; Cioffi, WG; Jarrar, D; Knöferl, MW; Song, GY; Wang, P, 2000)
"Although studies have shown that prolactin (Prl) and metoclopramide (Mcp) administration restores the depressed cell-mediated immune functions after hemorrhage, the underlying mechanism responsible for the immunostimulatory effects of Mcp remains unknown."	7.70	Insight into the mechanism by which metoclopramide improves immune functions after trauma-hemorrhage. ( Angele, MK; Ayala, A; Bland, KI; Chaudry, IH; Cioffi, WG; Knöferl, MW, 2000)
"Although metoclopramide (MCP) administration after trauma-hemorrhage restores the depressed immune functions, it remains unknown whether this agent has any salutary effects on the depressed cardiovascular and hepatocellular functions under those conditions."	3.70	Metoclopramide: a novel adjunct for improving cardiac and hepatocellular functions after trauma-hemorrhage. ( Bland, KI; Chaudry, IH; Cioffi, WG; Jarrar, D; Knöferl, MW; Song, GY; Wang, P, 2000)
"Although studies have shown that prolactin (Prl) and metoclopramide (Mcp) administration restores the depressed cell-mediated immune functions after hemorrhage, the underlying mechanism responsible for the immunostimulatory effects of Mcp remains unknown."	3.70	Insight into the mechanism by which metoclopramide improves immune functions after trauma-hemorrhage. ( Angele, MK; Ayala, A; Bland, KI; Chaudry, IH; Cioffi, WG; Knöferl, MW, 2000)

Research

Studies (7)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

All-cause 28-day Mortality Rate.

Antibiotic-free Days

Incidence of Prolonged Lymphopenia (Absolute Lymphocyte Count Less Than or Equal to 1,000/mm³ for > or Equal to 7 Days)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (28.57)	18.7374
1990's	1 (14.29)	18.2507
2000's	3 (42.86)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (14.29)	2.80

Authors	Studies
Dorgalaleh, A	1
Dabbagh, A	1
Tabibian, S	1
Bahraini, M	1
Rafieemehr, H	1
Spelina, KR	1
Gerber, HR	1
Pagels, IL	1
Zellweger, R	1
Wichmann, MW	1
Ayala, A	3
Chaudry, IH	4
Jarrar, D	1
Wang, P	1
Song, GY	1
Knöferl, MW	2
Cioffi, WG	2
Bland, KI	2
Angele, MK	2
Schwacha, MG	1
Bruhn, HD	1
Kirch, W	1
Ohnhaus, EE	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Critical Illness Stress-induced Immune Suppression Prevention Trial[NCT00395161]	Phase 3	293 participants (Actual)	Interventional	2007-04-30	Terminated (stopped due to Terminated for futility on 11/30/09 based on the recommendation of the DSMB)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	participants (Number)
Enteral Zinc, Selenium, Glutamine, and IV Metoclopramide	15
Enteral Whey Protein, IV Saline	8

Intervention	Days (Median)
Enteral Zinc, Selenium, Glutamine, and IV Metoclopramide	1
Enteral Whey Protein, IV Saline	2

What is reported is the number of participants with counts qualifying as lymphopenia. (NCT00395161)
Timeframe: from time of PICU admission till discharge from PICU

Rate of Nosocomial Infection or Clinical Sepsis Per 100 Study Days

The Primary Endpoint of This Study is the Median Time Between Admission to the PICU and Occurrence of Nosocomial Infection or Clinical Sepsis in PICU Patients Who Have Endotracheal Tubes, Central Venous Catheters, or Urinary Catheters.

Intervention	participants (Number)
Enteral Zinc, Selenium, Glutamine, and IV Metoclopramide	5
Enteral Whey Protein, IV Saline	12

Intervention	Mean number of events per 100 study days (Mean)
Daily Nutriceutical Supplementation	4.99
Whey Protein	4.83

(NCT00395161)
Timeframe: 48 hours after admission until 5 days after discharged from the PICU

Article	Year
Persistent hiccups in a patient with mild congenital factor V deficiency and COVID-19; clinical and laboratory finding of a rare bleeding disorder. International journal of laboratory hematology, 2021, Volume: 43, Issue:2 Topics: Chlorpromazine; COVID-19; COVID-19 Drug Treatment; Factor V Deficiency; Hematologic Tests; Hemorrhag	2021
Metoclopramide: a novel and safe immunomodulating agent for restoring the depressed macrophage immune function after hemorrhage. The Journal of trauma, 1998, Volume: 44, Issue:1 Topics: Animals; Dopamine Antagonists; Hemorrhage; Interleukin-1; Interleukin-2; Interleukin-3; Interleukin-	1998
Metoclopramide: a novel adjunct for improving cardiac and hepatocellular functions after trauma-hemorrhage. American journal of physiology. Endocrinology and metabolism, 2000, Volume: 278, Issue:1 Topics: Animals; Cardiac Output; Dopamine Antagonists; Heart; Hemorrhage; Interleukin-6; Liver; Male; Metocl	2000
Insight into the mechanism by which metoclopramide improves immune functions after trauma-hemorrhage. American journal of physiology. Cell physiology, 2000, Volume: 279, Issue:1 Topics: Animals; Cell Division; Cells, Cultured; Hemorrhage; Immune System; Interleukin-1; Interleukin-6; Ly	2000
[Drug interactions. Metoclopramide-phenprocoumon]. Deutsche medizinische Wochenschrift (1946), 1987, May-01, Volume: 112, Issue:18 Topics: 4-Hydroxycoumarins; Aged; Drug Interactions; Female; Hemorrhage; Humans; Metoclopramide; Phenprocoum	1987

metoclopramide and Bleeding